Catastrophic optical damage

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Retrieved on: 
Wednesday, November 30, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Probiotic, Risk, MAD, AbbVie, GI, Therapy, Roche, Synthetic biology, Homocystinuria, Inflammatory bowel disease, Phenylketonuria, Nature, Catastrophic optical damage, Șaeș, Blood, Patient, IBD, PKU, Genetic engineering, Gout, Fast Track, Workforce, Diet, Plasma, FDA, Methionine, Feces, Food, Uric acid, Urine, Ginkgo, Cystathionine, Disease, CBS, Orphan, Frequency, News, Research, AES, Clinical trial, Safety, Metabolism, AUC, Frank Lenti, Homocysteine, AE, Gastrointestinal tract, Absorption, ODD, Pharmaceutical industry, Risk management, Dietary supplement, Mineral wool, HCU

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB1353 has achieved proof of mechanism and positive results in a Phase 1 study in healthy volunteers treated with multiple ascending doses of SYNB1353.  SYNB1353 is an orally administered, non-systemically absorbed drug candidate designed to consume methionine in the GI tract for the potential treatment of homocystinuria (HCU). 

Key Points: 
  • SYNB1353 is an orally administered, non-systemically absorbed drug candidate designed to consume methionine in the GI tract for the potential treatment of homocystinuria (HCU).
  • The Company also shared that the FDA has granted Orphan Drug Designation (ODD) to SYNB1353 for the treatment of HCU.
  • This dietary model was intended to capture in healthy volunteers a transient elevation in methionine following a meal challenge, in order to demonstrate proof of mechanism of consumption of methionine by SYNB1353.
  • Dosing of SYNB1353 resulted in a reduction in plasma methionine when measured over 24-hours as area under the curve (AUC) following a methionine meal challenge.